v3.25.2
Segment Information - Schedule of Reconciliation of Significant Segment Expenses (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2025
Mar. 31, 2025
Jun. 30, 2024
Mar. 31, 2024
Jun. 30, 2025
Jun. 30, 2024
Segment Reporting Information [Line Items]            
Total external R&D program expenses $ 17,045   $ 17,452   $ 35,019 $ 32,525
Total internal R&D expenses 6,232   10,092   15,683 21,887
Total R & D Expenses 23,277   27,544   50,702 54,412
Total G & A expenses 8,079   6,733   15,038 13,898
Total restructuring expenses 17,486       17,486  
Other segment (income) expense [1] (860)   (2,713)   (2,107) (5,829)
Segment net loss 47,982 $ 33,137 31,564 $ 30,917 81,119 62,481
ARTISTRY-6            
Segment Reporting Information [Line Items]            
Total external R&D program expenses 4,471   1,796   8,700 3,832
ARTISTRY-7            
Segment Reporting Information [Line Items]            
Total external R&D program expenses 1,540   3,693   4,849 10,790
Early Discovery Programs            
Segment Reporting Information [Line Items]            
Total external R&D program expenses 2,464   840   5,330 1,442
Employee-Related            
Segment Reporting Information [Line Items]            
Total internal R&D expenses 4,415   7,394   11,893 16,508
Total G & A expenses 3,061   3,567   5,843 7,727
Total restructuring expenses 9,457       9,457  
Other External R&D Program Expenses            
Segment Reporting Information [Line Items]            
Total external R&D program expenses [2] 8,570   11,123   16,140 16,461
Other Internal R&D Expenses            
Segment Reporting Information [Line Items]            
Total internal R&D expenses [3] 1,817   2,698   3,790 5,379
Other G&A expenses            
Segment Reporting Information [Line Items]            
Total G & A expenses [4] 5,018   $ 3,166   9,195 $ 6,171
Other restructuring expenses            
Segment Reporting Information [Line Items]            
Total restructuring expenses [5] $ 8,029       $ 8,029  
[1] Other non-operating (income) expense included in segment net loss includes interest income, tax expense, and other non-operating income and expense.
[2] Other external R&D program expenses included in segment net loss include expenses related to other clinical trials and general external program expenses.
[3] Other internal R&D expenses included in segment net loss include expenses related to occupancy and depreciation.
[4] Other G&A expenses included in segment net loss include expenses related to professional fees, information technology, depreciation, and other general G&A expenses.
[5] Other restructuring expenses include contract termination costs, impairment and asset write-offs incurred in connection with our reduction-in-force and the termination of certain development programs.